Crossmark

Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy

Crossref DOI link: https://doi.org/10.1038/s41417-018-0034-1

Published Online: 2018-06-29

Published Print: 2019-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rossignoli, Filippo https://orcid.org/0000-0001-7838-1542
Grisendi, Giulia

Spano, Carlotta

Golinelli, Giulia

Recchia, Alessandra

Rovesti, Giulia

Orsi, Giulia

Veronesi, Elena

Horwitz, Edwin M.

Dominici, Massimo
Funding

Funding for this research was provided by:

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) (12755, 17326, 17326, 12755, 17326, 12755, 17326)

Associazione Sostegno Ematologia e Oncologia Pediatrica (Italy)
License Information

Text and Data Mining valid from 2018-06-29
More Information

Article History

Received: 22 March 2018

Revised: 23 May 2018

Accepted: 31 May 2018

First Online: 29 June 2018

Compliance with ethical standards

:

: MD is founder of Rigenerand srl, a University start-up company developing gene therapy approaches for cancer. MD is also member of the Board of Directors of Rigenerand srl. MD interests are managed by University of Modena and Reggio Emilia in accordance with their conflict of interest policies. CS and GG are currently employed by Rigenerand srl. The remaining authors declare that they have no conflict of interest.